editorinchief@ijrtmr.com +91 9840521421 Scholarly Open Access, Peer-reviewed, Refereed Journal e-ISSN 2583-0368 Since 2021
  1. Home
  2. Archives
  3. 2026
  4. Vol. 6 Issue 3
  5. Article
Review Article

Clinical Studies of Rabies Vaccines in India: A Review and Pooled Analysis of Immunogenicity and Safety Outcomes

  • Paper ID 355
  • Volume 6, Issue 3
  • Pages 55-65
  • Published Online: May-June 2026
  • 30 Views
Open Access Peer Reviewed Crossref DOI

Authors

  • Shaitan Singh1
  • Nidhi Tyagi2
  • Nitin Kumar3

1 2 3 Department of Pharmacology, Saraswathi College of Pharmacy, Anwarpur, Uttar Pradesh, India.

Article Information

Published Online
May-June 2026
Pages
55-65
Article Type
Review Article
Check for updates
check update

Abstract

View PDF

Rabies remains one of the deadliest vaccine-preventable zoonoses, with near-universal fatality once clinical symptoms develop. India bears a disproportionate share of the global burden, contributing a substantial proportion of annual rabies deaths. Despite the availability of highly effective modern cell-culture rabies vaccines, gaps persist in post-exposure prophylaxis (PEP) delivery, pre-exposure prophylaxis (PrEP) uptake, and integration into national immunization efforts. Numerous clinical studies across India have evaluated purified chick embryo cell vaccines (PCECV), purified Vero cell rabies vaccines (PVRV), indigenous vaccines, intradermal (ID) regimens, and abbreviated schedules. This review synthesizes these investigations, focusing on pooled immunogenicity and safety outcomes and their public health relevance. Across studies, modern cell-culture vaccines consistently achieved high seroprotection rates, often approaching 100% by Day 14. Neutralizing antibody titers exceeded the accepted protective threshold of 0.5 IU/mL, with geometric mean titers typically ranging from 6 to 14.5 IU/mL across comparative trials, regardless of whether administered intramuscularly or intradermally. Safety profiles were uniformly favorable, with no vaccine-related deaths, fatal anaphylaxis, or rabies cases among individuals completing PEP. Overall, Indian evidence demonstrates that these vaccines are highly immunogenic and safe across routes and regimens. Intradermal schedules, including shortened protocols, offer comparable efficacy with added advantages of lower cost and operational feasibility in high-burden settings. Indigenous vaccines perform comparably to internationally marketed alternatives. These findings support expanded adoption of intradermal strategies and inform national and global rabies elimination efforts.

APC from ₹1200 + 18% GST

Peer-reviewed open access₹1200 Indian (₹1400 with DOI)$80 USD internationalpaid after acceptance Peer-reviewed open access₹1200 Indian$80 USD international ₹1200 Indian · $80 intl

  • CrossRef DOI
  • ISSN 2583-0368
  • Open Access
  • Peer Reviewed
  • Plagiarism Checked
  • Google Scholar
Submit Paper